Migraine Biochemistry: CGRP & Beyond
You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!
Key Questions
- ¿Qué es el péptido relacionado con el gen de la calcitonina (CGRP) y qué papel juega en la enfermedad de la migraña?
- ¿Qué medicamentos interrumpen la vía del CGRP para ayudar en el manejo de los ataques de migraña?
- ¿Cómo han beneficiado los medicamentos inhibidores de CGRP a quienes tienen migraña?
- ¿Qué sabemos hasta ahora sobre los posibles efectos secundarios de los medicamentos dirigidos al CGRP?
- ¿Por qué algunas personas no responden tan bien como otras a los inhibidores de CGRP?
- ¿Qué es el polipéptido activador de la adenilato ciclasa pituitaria (PACAP) y qué papel juega en el tratamiento de la migraña?
- ¿Podrían los síntomas de la migraña de un individuo derivarse potencialmente tanto de las vías del CGRP como del PACAP?
- ¿En qué otras sustancias están investigando actualmente los investigadores para tratamientos potenciales?
- ¿Cómo puede ayudarnos a comprender las diferentes manifestaciones de la migraña el aprender más sobre los medicamentos existentes?
- ¿Cuánto potencial hay para tratamientos de la migraña más allá del CGRP?
Interview Notes
- Study: “Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA”
- Article: “PACAP-Targeted Antibody Lu AG09222 Demonstrates Positive Results in Phase 2 Migraine Trial”
- Study: “PAR2 activation in the dura causes acute behavioral responses and priming to glyceryl trinitrate in a mouse migraine model”
Treatments Mentioned
- Almotriptan (Axert)
- Amitriptyline
- Atogepant (Qulipta)
- CGRP inhibitors
- CGRP monoclonal antibodies (mAbs)
- CGRP small-molecule receptor antagonists (gepants)
- Eletriptan (Relpax)
- Eptinezumab (Vyepti)
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Frovatriptan (Frova)
- Galcanezumab (Emgality)
- Naratriptan (Amerge)
- Propranolol
- Rimegepant (Nurtec)
- Rizatriptan (Maxalt)
- Sumatriptan (Imitrex)
- Topiramate (Topamax)
- Triptans
- Ubrogepant (Ubrelvy)
- Zavegepant (Zavzpret)
- Zolmitriptan (Zomig)
Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.
This is a Spanish translation of an expert interview from the Migraine World Summit 2024. All interviews have been carefully translated and medically reviewed.
Peter Goadsby, MD, PhD, FRS
Professor of Neurology and Neurologist
King's College London
Dr. Peter J. Goadsby is one of the world’s leading headache neurologists and researchers. He is a professor at King’s College London and an emeritus professor at the University of California, Los Angeles (UCLA). Dr. Goadsby is on the board of directors of the American Headache Society, and is also a trustee for The Migraine Trust.
He serves on the scientific advisory board and executive committee for the American Registry for Migraine Research (ARMR). He was one of the first to explore calcitonin gene-related peptide (CGRP), the protein known for its involvement in migraine. This discovery has been instrumental in creating the new class of medications CGRP blockers, including Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), Nurtec ODT (rimegepant), Qulipta (atogepant), and Vyepti (eptinezumab).
Purchase full access to the entire 2024 Summit. Includes:
- All expert interviews with separate audio (MP3) files & transcripts
- Lifetime on-demand access with no annual fee to 2024 Summit
- Interview Summaries
- Treatment Guidelines
- And much more!
Related Talks for: Day 2 (2024)
How Much Is Too Much Excedrin Migraine?
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
The Gut Factor: Exploring the Role of Digestive Health in Migraine
Vince Martin, MD, AQH
Menopause, Perimenopause & Migraine
Christine Lay, MD, FAHS
Somos una organización sin fines de lucro que nuclea personas con migraña y otras cefaleas, sus familiares y los profesionales que acompañan a estas personas.
Damos apoyo a las personas que sufren de migraña y cefaleas a través de la educación, el acompañamiento y la promoción en el tema.
Nos comprometemos a apoyar a los pacientes, capacitar a los profesionales de la salud, visibilizar y sensibilizar a la sociedad sobre el impacto de estas condiciones.
¡Juntos le ganamos al dolor de cabeza!
Noticing new symptoms? Struggling with Chronic Migraine? Need hope? Try these Learning Tracks to more to get the most out of your Summit experience.
